ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-OR05

Immunological Response in Dialysis and Kidney Transplant Patients with SARS-CoV-2 Infection

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Affatato, Stefania, Universita degli Studi di Brescia, Brescia, Lombardia, Italy
  • Mescia, Federica, Universita degli Studi di Brescia, Brescia, Lombardia, Italy
  • Quaresima, Virginia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Fiorini, Chiara, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Gaggiotti, Mario, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Bossini, Nicola, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Gaggia, Paola, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Badolato, Raffaele, Universita degli Studi di Brescia, Brescia, Lombardia, Italy
  • Notarangelo, Luigi D., National Institute of Allergy and Infectious Diseases Laboratory of Clinical Immunology and Microbiology, Bethesda, Maryland, United States
  • Chiarini, Marco, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Brescia, Lombardia, Italy
  • Scolari, Francesco, Universita degli Studi di Brescia, Brescia, Lombardia, Italy
  • Alberici, Federico, Universita degli Studi di Brescia, Brescia, Lombardia, Italy
Background

Mortality for COVID-19 in dialysis(HD) and kidney transplant(TX) patients(pts) is 30%. In these pts the immunology of the disease has been poorly explored.

Methods

32 HD or TX pts hospitalized for COVID-19 (COV), of which 13 with benign course(PosCOV) and 19 who died or developed ARDS(NegCOV), 10 controls(HC) and 12 HD/TX without COVID-19(PC), have been included. Lymphocytes subsets, dendritic cells(DC) and monocytes activation (MA) have been explored.

Results

COV showed lower counts of CD4+, CD8+, CD56+, CD19+, DC and higher counts of terminally differentiated CD19+ compared to HC and PC; CD4+, CD8+, CD19+ and MA were significantly lower in NegCOV than PosCOV. Compared to HD, TX showed lower CD56+, pDC and MA.

Conclusion

The COV group showed immunological alterations compared to HC and PC with deeper alterations of the innate immune system in TX pts with COVID-19.

CharacteristicsPosCOV (13)NegCOV (19)p
Age (years; n - IQR)57 (48-73)73 (60-83)0.035
Male/female (n)13/013/60.035
HD/TX pt (n)5/812/70.280
WBC
(NV 4.00 – 10.80 x10^3/uL; μe - IQR)
7.045 (4.35-7.61)6.240 (3.93-8.49)0.668
Lymphocytes
(NV 0.90 – 4.00 x10^3/uL; μe - IQR)
0.74 (0.51-1.4)0.43 (0.36-1.02)0.026
Neutrophils
(NV 1.50 – 8.00 x10^3/uL; μe - IQR)
5.04 (2.93-6.34)4.89 (3.06-7.75)0.451
Monocytes (NV 0.2-1 x10^3/uL; μe - IQR)0.57 (0.50-0.67)0.41 (0.30-0.47)0.003